The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
biotech is hot with all the covid hysteria. get it now. said hysteria goes bye bye when election is over. ------ 8:20 am ET October 13, 2020 (Benzinga) Print Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ: TXG) Acceleron Pharma Inc (NASDAQ: XLRN) Adaptive Biotechnologies Corp (NASDAQ: ADPT) Applied Molecular Transport Inc. (NASDAQ: AMTI) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) argenx SE – ADR (NASDAQ: ARGX) Beigene Ltd (NASDAQ: BGNE) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) Blueprint Medicines Corp (NASDAQ: BPMC) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT) Cardiff Oncology Inc (NASDAQ: CRDF) CareDx Inc (NASDAQ: CDNA) Castle Biosciences Inc (NASDAQ: CSTL) Denali Therapeutics Inc (NASDAQ: DNLI) Fate Therapeutics Inc (NASDAQ: FATE) Immunovant Inc (NASDAQ: IMVT) Insmed Incorporated (NASDAQ: INSM) Intellia Therapeutics Inc (NASDAQ: NTLA) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Kronos Bio Inc (NASDAQ: KRON) (went public Friday) Kura Oncology Inc (NASDAQ: KURA) Kymera Therapeutics Inc (NASDAQ: KYMR) Lantern Pharma Inc. (NASDAQ: LTRN) Natera Inc (NASDAQ: NTRA) Nevro Corp (NYSE: NVRO) Novocure Ltd (NASDAQ: NVCR) Orphazyme A S ADR (NASDAQ: ORPH) Repligen Corporation (NASDAQ: RGEN) Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Pacific Biosciences of California Inc (NASDAQ: PACB) SpringWorks Therapeutics Inc (NASDAQ: SWTX) Stoke Therapeutics Inc (NASDAQ: STOK) Surface Oncology Inc (NASDAQ: SURF) -moved on reports of the company exploring a potential sale and Bristol-Myers Squibb Co (NYSE: BMY) expressing interest Tcr2 Therapeutics Inc (NASDAQ: TCRR) TG Therapeutics Inc common stock (NASDAQ: TGTX) Turning Point Therapeutics Inc (NASDAQ: TPTX) Twist Bioscience Corp (NASDAQ: TWST) Veracyte Inc (NASDAQ: VCYT) Vericel Corp (NASDAQ: VCEL) Zai Lab Ltd – ADR (NASDAQ: ZLAB) West Pharmaceutical Services Inc. (NYSE: WST) Zoetis Inc (NYSE: ZTS)
This has been a strong ETF this year. Weekly chart relative to SPY I make a list of the ETF holdings in tradingview, /ARKG, e.g. NVTA/ARKG, CRSP/ARKG, PACB/ARKG to try to find the ones that are strong within the ETF.
Dipping toes into PACB and BNGO. June calls on PACB for $23 and bought shares of BNGO $2.10 BNGO is a penny stock but has a mapping machine with 70% less errors than PACB, is my understanding. This industry is all very new to me. Im trying to get up to speed.